US2005026980A1PendingUtilityA1

Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1H-[1,2,4]-triazole for the treatment of autoimmune diseases

Assignee: SIGMA TAU IND FARMACEUTIPriority: May 3, 2002Filed: Mar 30, 2004Published: Feb 3, 2005

Est. expiryMay 3, 2022(expired)· nominal 20-yr term from priority

Inventors:Luca Battistini Giovanna Borsellino Rita De Santis Paolo Carminati

A61P 37/02A61P 43/00A61P 37/06A61P 29/00A61P 25/00A61P 27/02A61P 19/02A61K 31/4196

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and rheumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-methoxy-1H-1,2,4-tirazole. The present invention further discloses a method for inhibiting γδ T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.

Claims

exact text as granted — not AI-modified

1 - 8 . canceled.  
     
     
         9 . A method for treating uveitis in a subject in need thereof, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole.  
     
     
         10 . The method of  claim 9 , wherein said subject is a mammal.  
     
     
         11 . The method according to  claim 9 , wherein said subject is a human.

Join the waitlist — get patent alerts

Track US2005026980A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.